With ASCO data tallied, Bristol-Myers loses ground to Merck in I-O field
admin 7th June 2017 Uncategorised 0Thanks to a raft of promising Keytruda results—in tandem with Incyte’s epacadostat, in certain high-risk breast cancers and in combination with chemo in lung cancer—industry watchers crowned Merck the immuno-oncology field’s weekend victor against rival Bristol-Myers Squibb.
More: With ASCO data tallied, Bristol-Myers loses ground to Merck in I-O field
Source: fierce